BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Pozen, Inc. 

6330 Quadrangle Drive, Suite 240

Chapel Hill  North Carolina  27514  U.S.A.
Phone: 919-490-0012 Fax:


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Pozen, Inc. (POZN) Reports Third Quarter 2014 Results 11/6/2014 11:48:37 AM
Pozen, Inc. (POZN) Announces November 6th Webcast Of Third Quarter 2014 Results 10/30/2014 10:22:24 AM
Pozen, Inc. (POZN) Announces Receipt Of Three Patents From The United States Patent And Trademark Office 10/23/2014 9:38:28 AM
Pozen, Inc. (POZN) Takes Another Step To No Longer Being A Drug Developer; Shrinks Workforce 8/22/2014 6:22:49 AM
Pozen, Inc. (POZN) Announces U.S. Rights For TREXIMET® Have Been Acquired By Pernix Therapeutics, Inc. (PTX) 8/20/2014 8:32:41 AM
Pozen, Inc. (POZN) Announces August 7th Webcast Of Second Quarter 2014 Results 7/25/2014 9:30:18 AM
Pozen, Inc. (POZN) Resubmits PA8140/PA32540 NDA 7/2/2014 9:52:55 AM
Pozen, Inc. (POZN) Announces May 8th Webcast Of First Quarter 2014 Results 5/1/2014 2:59:10 PM
Pozen, Inc. (POZN) Submits Final Study Report For PA8140/PA32540 Phase 1 Study On Schedule 4/2/2014 8:32:57 AM
Pozen, Inc. (POZN) To Present At The ROTH Capital Partners 26th Annual Growth Stock Conference 3/4/2014 8:15:13 AM
12345678910...